Back to Journals » Clinical Ophthalmology » Volume 9

Unilateral transient mydriasis and ptosis after botulinum toxin injection for a cosmetic procedure

Authors Akkaya S, Kökcen HK, Atakan T

Received 19 October 2014

Accepted for publication 11 December 2014

Published 12 February 2015 Volume 2015:9 Pages 313—315

DOI https://doi.org/10.2147/OPTH.S76054

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Scott Fraser


Sezen Akkaya,1 Hatice Kübra Kökcen,1 Tuğba Atakan2

1Fatih Sultan Mehmet Education and Training Hospital, Ophthalmology Clinics, Bostanci, Istanbul, 2Aksaray Hospital, Ophthalmology Clinics, Konya, Turkey

Abstract: We report a case of unilateral transient mydriasis and ptosis after botulinum toxin injection applied by a medical doctor for a cosmetic procedure. A 36-year-old nurse was referred to our eye clinic with unilateral mydriasis and ptosis in the right eye 3 days after botulinum toxin injection for a cosmetic procedure. Botulinum toxin was applied to her eye by a doctor at her hospital who was not an ophthalmologist. She was treated with topical apraclonidine 0.5% ophthalmic solution. Her ptosis decreased to 2 mm with apraclonidine and her visual axis improved. Mydriasis was present for 3 weeks and then disappeared. Mild ptosis continued for 3 months, then resolved completely. Patients seeking treatment with botulinum toxin A for cosmetic purposes should be warned about the possibility of ptosis and mydriasis after injection. If these side effects are seen, the patient must be referred to an ophthalmologist for appropriate management.

Keywords: botulinum toxin, mydriasis, ptosis


Introduction

Botulinum toxin A (BTX-A) was first used for esthetic purposes in 1990 to reduce wrinkles caused by facial muscle. Its effect starts 3–4 days after application and lasts for 4–6 months.1

All medical doctors, from plastic surgeons to dermatologists, can administer BTX-A injections effectively and safely. Ophthalmologists are also performing this procedure for blepharospasm.2 Patients may also present to an ophthalmologist because of the ophthalmological side effects of BTX-A. For this reason, the ophthalmologist must take a detailed history from the patient if there is ptosis.

Case report

A 36-year-old woman was referred to the eye clinic at Fatih Sultan Mehmet Training and Research Hospital with unilateral mydriasis and ptosis in the right eye (Figures 1 and 2). Right upper eyelid margin was at the level of the pupil, 3 days after botulinum toxin injection for a cosmetic procedure. The patient was a nurse and the BTX-A was administered by a doctor at her hospital who was not an ophthalmologist. The total cumulative dose of BTX-A injected was 35 IU to the right side and 25 IU to the left side. BTX-A was injected bilaterally to the orbicularis oculi, corrugator supercili, and procerus muscles to reduce the wrinkles.

Figure 1 Mydriasis after botulinum toxin injection in the right eye.

Figure 2 Ptosis after botulinum toxin injection in the right eye.

On presentation, her right pupil measured 6 mm and was fixed, with no direct or consensual response to light, and her left pupil was 3 mm and had a normal light response. There was a 3 mm difference in diameter between the pupils.

The patient had no previous history of lid surgery or botulinum toxin injection. Best corrected visual acuity was 20/20 in both eyes. Biomicroscopic examination of the anterior segment was normal. Intraocular pressure was 12 mmHg in both eyes. Thorough dilated fundus examination was normal. Margin reflex distance was 2 mm in the right eye and 6 mm in the left eye. Levator function was 10 mm in the right eye and 16 mm in the left eye. Bell’s phenomenon was normal. There was no abnormality of extraocular movements and no jaw winking was observed (Figure 1). Cranial magnetic resonance imaging revealed no optic nerve or cerebral dysfunction. There was no apparent afferent pupillary defect, as judged by the reaction of the left pupil.

The patient was counseled that the ptosis and mydriasis would not be permanent. She was treated with topical apraclonidine 0.5% ophthalmic solution, which decreased her ptosis to 2 mm. Her visual axis improved, and her eye opening improved after 3 days of treatment with apraclonidine. On examination, there was only a 2 mm ptosis in the right eye (margin reflex distance 4 mm) but the mydriasis was unchanged. Her mydriasis was present for 3 weeks and then disappeared. Mild ptosis continued for 3 months, then resolved completely (Figure 3).

Figure 3 Ptosis and mydriasis resolved.

Discussion

Botulinum neurotoxins inhibit the release of acetylcholine and act primarily at the peripheral cholinergic synapses. These agents act at the neuromuscular junction in skeletal muscle, causing transient muscle paresis.3 However, botulinum toxins also inhibit the release of acetylcholine at the sympathetic ganglia and at the preganglionic and postganglionic nerve terminals in the parasympathetic nervous system.4 People who are systemically poisoned with botulinum toxins characteristically have fixed mid-dilated pupils due to paralysis of the sympathetic and parasympathetic innervation to the iris. Botulinum toxins could therefore cause pupil dilatation by uptake into the parasympathetic neurons at the level of the ciliary ganglion or the parasympathetic neuromuscular junctions in the sphincter pupillae of the iris.5 It has been shown in animal studies that botulinum toxin injected intracamerally or near the ciliary ganglion causes mydriasis.3 Persistent mydriasis has been reported after medial rectus muscle injection of botulinum toxin for esotropia in a child.6

There are no reports in the literature on reversible mydriasis secondary to cosmetic procedures. We believe that botulinum toxin had been administered at a high dose in our patient, and that the cumulative BTX-A dose to the right eye was more than that to the left eye.

Transient mydriasis has been observed with experimental retrobulbar botulinum toxin injection at doses of 1.5 and 2.5 ng in rats, with the mydriasis resolving within 12 weeks.7 In a rabbit model, intravitreal injection of 1.25 to 25 units caused mydriasis lasting for 3 weeks. Five cases of transient mydriasis have been reported in humans. In these five cases, after botulinum toxin injection to extraocular muscles, mostly the lateral rectus muscles, transient mydriasis was shown with Adie’s pupils. The most likely suggested cause was injury to the ciliary ganglion, resulting in weakened accommodation. None of the cases, however, showed mydriasis persisting for more than a few weeks.7,8

Botulinum toxin can also cause ptosis. Prevention of ptosis requires care during injection and in the post-procedure period. When injecting botulinum toxin, care should be taken not to inject the lower frontalis or orbicularis oculi muscles at sites that are lateral to the mid-pupillary line, and the needle should be pointing superiorly away from the orbit to prevent the toxin from denervating the levator muscles that raise the eyelid, resulting in ptosis.9,10

Apraclonidine successfully reversed ptosis due to botulinum toxin injection in our patient. Apraclonidine is an alpha-adrenergic receptor agonist9 that directly stimulates sympathetic innervation of the superior tarsal muscle and decreases ptosis. There is currently no treatment for botulinum toxin-induced ptosis. Patients who suffer such a complication have to wait for several weeks until the effects of the toxin wear off. This case report suggests that apraclonidine can provide a reversal option for physicians and their patients.

Before botulinum injection for cosmetic purposes or to treat blepharospasm, patients should be warned about the possibility of developing toxin-induced ptosis and mydriasis. If this occurs, after evaluation of cranial magnetic resonance imaging, doctors who applied the botulinum toxin must refer the patient to an ophthalmologist for appropriate management.

Disclosure

The article has not been presented at any meeting, and no financial support was received from any public or private source in respect to this work. The authors have no financial or proprietary interest in any product, method, or material described herein.


References

1.

Münchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ. 2000;320:161–165.

2.

Baggio E, Ruban JM, Boizard Y. [Etiologic causes of ptosis about a series of 484 cases. To a new classification?]. J Fr Ophtalmol. 2002;25:1015–1020. French.

3.

Corridan P, Nightingale S, Mashoudi N, Williams AC. Acute angle-closure glaucoma following botulinum toxin injection for blepharospasm. Br J Ophthalmol. 1990;74:309–310.

4.

Zheng L, Azar D. Angle-closure glaucoma following periorbital botulinum toxin injection. Clin Experiment Ophthalmol. 2014;42:690–693.

5.

Hemmerdinger C, Srinivasan S, Marsh IB. Reversible pupillary dilation following botulinum toxin injection to the lateral rectus. Eye. 2006;20:1478–1479.

6.

Speeg-Schatz C. Persistent mydriasis after botulinum toxin injection for congenital esotropia. J AAPOS. 2008;12:307–308.

7.

Levy Y, Kremer I, Shovit S, Korczyn AD. The pupillary effects of retrobulbar injection of botulinum toxin A (Oculinum) in albino rats. Invest Ophthalmol Vis Sci. 1991;32:122–125.

8.

Klein AW. Complications with the use of botulinum toxin. Int Ophthalmol Clin. 2005;45:163–169.

9.

Omoigui S, Irene S. Treatment of ptosis as a complication of botulinum toxin injection. Pain Med. 2005;6:149–151.

10.

Hirsch R, Stier M. Complications and their management in cosmetic dermology. Dermatol Clin. 2009;27:507–520.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]